

OPIC
OFFICE DE LA PROPRIÉTÉ
INTELLECTUELLE DU CANADA



CIPO
CANADIAN INTELLECTUAL
PROPERTY OFFICE

(12) (19) (CA) **Demande-Application**

(21) (A1) **2,270,320**
(22) 1999/04/28
(43) 1999/10/28

(72) JOSEPH, Jamie William, CA
(72) BRUBAKER, Patricia Lee, CA
(71) JOSEPH, Jamie William, CA
(71) BRUBAKER, Patricia Lee, CA
(51) Int.Cl.⁶ A61K 38/26, A61K 9/16, A61K 45/08
(30) 1998/04/28 (60/083/092) US
(54) **NOUVELLE COMPOSITION MICROSPHERE**
(54) **NOVEL MICROSPHERE COMPOSITION**

(57) A novel microsphere composition is described. The composition contains a biocompatible oil that increases the release of an active agent from the microspheres. In a preferred embodiment the active agent is GLP-1 and the microsphere composition can be used to treat diabetes.



BP File No. 2223-084/MG

ABSTRACT OF THE DISCLOSURE

A novel microsphere composition is described. The composition contains a biocompatible oil that increases the release of an
5 active agent from the microspheres. In a preferred embodiment the active agent is GLP-1 and the microsphere composition can be used to treat diabetes.

- 38 -

WE CLAIM:

1. A microsphere composition comprising a biocompatible oil and a polymer capable of forming microspheres.
2. A composition according to claim 1 further comprising an
5 active agent.
3. A composition according to claim 1 or 2 wherein the microspheres are composed of a biodegradable polymer.
4. A composition according to claim 3 wherein the polymer is poly-lactide-co-glycolide (PLGA).
- 10 5. A composition according to claim 4 wherein the polymer is PLGA-COOH.
6. A composition according to claim 1 or 2 wherein the polymer is selected from the group consisting of polyesters, polyketals, polyorthoesters, polyanhydrides, polyacetals, polyureas, polycarbonates,
15 polyurethanes, polyamides and combinations thereof.
7. A composition according to any one of claims 1 to 6 wherein the biocompatible oil is olive oil.
8. A composition according to any one of claims 1 to 6 wherein the biocompatible oil is selected from the group consisting of olive oil,
20 canola oil, soybean oil, sunflower oil, coconut oil, safflower oil, cotton seed oil, peppermint oil and chili pepper oil.
9. A composition according to claim 2 wherein the active agent is selected from the group consisting of hormones, proteins, peptides,

- 39 -

peptide analogs, peptide derivatives, drugs, vaccines, antigens vitamins, carbohydrates and lipids.

10. A microsphere composition according to claim 2 comprising:
(a) a therapeutic peptide as the active agent; (b) olive oil as the
5 biocompatible oil; and (c) a poly-lactide-co-glycolide as the polymer that
forms the microspheres.
11. A composition according to claim 10 wherein the peptide is
present in an amount from about 1% to about 20% of the total
composition; the olive oil is present in an amount from about 20% to
10 about 70% of the total composition; and the poly-lactide-co-glycolide
microspheres are present in an amount from about 20% to about 79% of
the total composition.
12. A composition according to claim 10 wherein the peptide is
present in an amount of about 2% of the total composition; the olive oil is
15 present in an amount of about 50% of the total composition; and the poly-
lactide-co-glycolide microspheres are present in an amount of about 48% of
the total composition.
13. A composition according to claim 12 wherein the therapeutic
peptide is GLP-1.
- 20 14. A use of a composition according to any one of claims 2 to 13
to deliver an active agent to an animal.
15. A use of a composition according to any one of claims 2 to 13
to increase the bioactivity of an active agent in an animal.
16. A use of a composition according to any one of claims 1 to 13
25 to treat diabetes.

- 40 -

17. A use according to claim 16 wherein the microsphere composition is suitable for oral administration.
18. A method for preparing a microsphere composition comprising (a) adding a polymer capable of forming microspheres to a
5 biocompatible oil; (b) adding an active agent in an aqueous solution to the polymer and oil solution; (c) pouring the mixture into a non-solvent solution under conditions which allow for the spontaneous formation of microspheres containing the naturally occurring oil and the active agent.
19. A method according to claim 18 wherein the polymer is
10 dispersed in methylene chloride in step (a).
20. A method according to claim 18 or 19 wherein the non-solvent solution in step (c) is petroleum ether.

B&P File No. 2223-084/MG

Title: Novel Microsphere Composition

FIELD OF THE INVENTION

The present invention relates to a novel microsphere
5 composition containing a biocompatible oil that increases the release of an
active agent from the microspheres.

BACKGROUND OF THE INVENTION

Introduction

Therapeutic administration of peptide hormones has largely
10 been restricted to parenteral routes due to the inherent capacity of the
gastrointestinal tract to digest proteins. A number of different approaches
have been developed that bypass the digestive system, thereby permitting
systemic delivery of peptides and other therapeutic agents (1-7). The most
conventional method of peptide delivery is by injections but more recently
15 developed methods include continuous infusion pumps for hormones
such as gonadotropin-releasing hormone and glucagon-like peptide-1
(GLP-1) (8,9), nasal sprays for peptides including antidiuretic hormone and
calcitonin (3,4), mucosal dosage forms for insulin(10), and buccal tablets for
GLP-1 (1). Although these are relatively successful techniques for peptide
20 delivery, these approaches do have various limitations, including poor
patient compliance (11,12), as well as the potential for tissue damage at the
site of administration [eg lipodystrophy (13) and inhibition of nasal ciliary
activity when delivered by nasal sprays (14)]. Alternative, less invasive
routes of peptide delivery therefore continue to be a focus of investigation.

25 Recently, effective methods for encapsulating peptides and
other drugs into orally-available, biocompatible microspheres have been
developed (15-17). One important characteristic of these microspheres is
that they can adhere to the intestinal mucosal epithelium (18), which
slows their passage through the gastrointestinal system increasing their
30 chance of being absorbed (15). In addition, microspheres, such as poly-
lactide-co-glycolide (PLGA) and co-polymers of fumaric and sebacic acid
(poly(FA:SA)), have been reported to undergo lymphoid-mediated uptake
via Peyer's patches in the small intestine (15,19). Microspheres consisting
of polyanhydride co-polymers of poly(FA:SA) have also been shown to

- 2 -

traverse across the small intestine through both para- and intracellular routes, after which at least some of the microspheres are found lodged in the liver and spleen (15).

Consistent with the ability of these microspheres to reach the
5 systemic circulation, the oral bioavailability of dicumarol, an anti-coagulant, is increased 1.5- to 2-fold by encapsulation into poly(FA:SA) (15). A similar approach was also used for the successful oral delivery of the peptide hormone insulin (15). When insulin was encapsulated into these microspheres consisting of the polymers poly(fumaric acid) and
10 PLGA [poly(FA:PLGA), 50:50] and then given orally to rats, a decreased glycemic response to an intraperitoneal glucose tolerance test was observed (15). However caution must be taken when giving insulin orally due to insulin capacity to cause hypoglycemia. In the case of insulin the exact amount a person receives is very important because too much insulin will
15 result in hypoglycemia and too little will not prevent hyperglycemia. Therefore, although this new delivery system does show a lot potential for the treatment of diabetes and possibly other disorders, further studies are still required to control for the amount of insulin absorbed.

The insulintropic peptide, Glucagon-like peptide-1 (GLP-1),
20 has been proposed as a therapeutic agent for the treatment of type II diabetes (20,21) because of its ability to stimulate glucose-dependent insulin release (22,23) and possibly improve peripheral insulin sensitivity (24). GLP-1 has several advantages over insulin as for its potential for oral delivery, the most important of which is its apparent inability to cause
25 hypoglycemia even at high peptide concentrations. However, there are two major problems associated with the administration of this peptide: (A) The peptide has a short *in vivo* half-life of 0.9 minutes (25), and (B) currently the major route of administering GLP-1 in humans is by parenteral administration (26). The active form of GLP-1 is a 31 amino
30 acid hormone that is inactivated by the actions of dipeptidyl peptidase IV (DP IV) (25,27,28). To circumvent this inactivation the present inventors have utilized an analog of GLP-1, D-ala²-GLP-1, that was designed to be

- 3 -

resistant to DP IV-mediated degradation. However, even with this modification, this peptide lost its biological activity within 4 hours of subcutaneous (sc) administration.

In view of the foregoing, there is a need in the art to provide improved oral delivery systems for the administration of biologicals such as peptides, especially GLP-1.

SUMMARY OF THE INVENTION

The present invention relates to a novel microsphere composition. In particular, the present inventors have demonstrated that microsphere compositions containing an active agent and a biocompatible oil show an increase in the release rate of the active agent as compared to a microsphere composition without the oil.

Broadly stated, the present invention provides a microsphere composition comprising a biocompatible oil and a polymer capable of forming microspheres.

In one embodiment the microsphere composition additionally includes an active agent. Accordingly, the present invention provides a microsphere composition comprising (a) an active agent and (b) a biocompatible oil encapsulated in (c) a microsphere formulation.

The present invention also provides a method of delivering an active agent to an animal comprising administering an effective amount of a microsphere composition according to the invention to an animal in need thereof.

The invention also includes a method of increasing the bioactivity of an active agent comprising administering a microsphere composition according to the present invention to an animal in need thereof.

The invention further includes a method of treating diabetes comprising administering a microsphere composition comprising GLP-1 to an animal in need thereof.

The present invention further provides a method for preparing a microsphere composition comprising (a) adding a polymer

- 4 -

capable of forming microspheres to a biocompatible oil; (b) adding an active agent to the polymer and oil solution; (c) pouring the mixture into a non-solvent solution under conditions which allow for the spontaneous formation of microspheres containing the biocompatible oil and the active agent.

Other features and advantages of the present invention will become apparent from the following detailed description. It should be understood, however, that the detailed description and the specific examples while indicating preferred embodiments of the invention are given by way of illustration only, since various changes and modifications within the spirit and scope of the invention will become apparent to those skilled in the art from this detailed description.

BRIEF DESCRIPTION OF THE DRAWINGS

The invention will now be described in relation to the drawings in which:

Figures 1A and B show the High Performance Liquid Chromatography (HPLC) analysis of native GLP-1 and D-ala²-GLP-1 after incubation with DP-IV *in vitro*. FIG. 1A shows HPLC profiles of undigested and DP-IV digested native GLP-1 and D-ala²-GLP-1 (after a 3 hour digest). FIG. 1B is a graph showing combined HPLC data for the change in elution position between digested vs. undigested native GLP-1 and D-ala²-GLP-1 (*P<0.05). This data shows that our new analog is resistant to DP-IV degradation.

Figures 2A and B are graphs showing the effects of 10 ug of GLP-1 and 10 ug of D-ala²-GLP-1 on the glycemic response to oral glucose in mice. FIG. 2A is a graph showing changes in glycemia in response to 1.5 mg glucose/g body weight (diamonds: PBS; squares, 10 ug native GLP-1; and triangles: 10 ug D-ala²-GLP-1). FIG. 2B is a graph showing the area under the curve (AUC) for the glycemic responses. * P<0.05, ** P<0.01, *** P<0.001 for D-ala²-GLP-1 vs PBS; # P<0.05 for GLP-1 vs PBS; and +++ P<0.001 for D-ala²-GLP-1 vs GLP-1. This data shows that the new analog of GLP-1 is more potent than native GLP-1.

- 5 -

Figure 3 is a bar graph showing percent of total peptide released from PLGA-COOH microspheres over a 9 hour incubation *in vitro*. Background #1 and #2: PLGA-COOH microspheres with olive oil only (n=1); 2% Glucagon: PLGA-COOH microspheres with glucagon (n=2);
 5 18%alb/2%Gluc: PLGA microspheres with 18% albumin and 2% glucagon (n=2); 30%olv/2%Gluc: PLGA microspheres with 30% olive oil and 2% glucagon (n=1); 50%olv/2%D-ala²: PLGA microspheres with 50% olive oil and 2% D-ala²-GLP-1 (n=4); and 50%olv/2%Hex: PLGA microspheres with 50% olive oil and 2% hexenoyl-GLP-1 (n=2). These results show that we
 10 were able to develop a microsphere preparation that releases most of its peptide over a 9 hour period.

Figures 4A-C are graphs showing the release profile of PLGA-COOH-50% olive oil microspheres loaded with either 2% glucagon (n=2) (FIG. 4A), 2% D-ala²-GLP-1 (n=4) (FIG. 4B) or 2% hexenoyl-GLP-1
 15 (n=2) (FIG. 4C). Although these experiments were carried out over an 80 hour period, only the first 48 hours is shown as there was no further release of the peptide after this period. These results show that our microspheres release their peptide with an initial burst at t=1 hour followed by a gradual release of peptide with a peak at 7-9 hours.

20 Figure 5 is a transmission electron microscopy (TEM) analysis of the size of PLGA-COOH-microspheres. These experiments were done on microspheres without any peptide or olive oil. These results show that the average size of the microspheres was 0.96 μ m in size (n=3).

Figure 6 is a graph showing the analysis of the olive oil
 25 content in microspheres. GLP-1 & OO bar is microspheres containing 50% olive oil and 2% D-ala²-GLP-1; Olive Oil alone bar is microspheres containing only 50% olive oil; Polymer bar represents empty microspheres that have no olive oil or peptide. The line represents the theoretical olive oil content of the microspheres. These results show that our microspheres
 30 have incorporated 60% of the added olive oil during their preparation.

Figure 7 is a graph showing the area under the curve of the delta blood glucose levels following repeated OGTT in normal CD1 mice at

- 6 -

0, 4 and 8 hours. Microspheres made of either 50% PLGA-COOH-50% olive oil (empty microspheres) or 48% PLGA-COOH-50% olive oil-2% peptide were given at t=0 hrs: **First Bar**, empty microspheres given *ip* (control#1; n=12); **Second Bar**, 5µg D-ala²-GLP-1 given *sc* (n=6); **Third Bar**, *ip* injection of microspheres containing 2% D-ala²-GLP-1 (equivalent to 50µg of peptide) (n=6); **Fourth Bar**, orally administered microspheres containing D-ala²-GLP-1 (equivalent to 250µg of peptide) (n=9); **Fifth Bar**, 250µg of D-ala²-GLP-1 given orally (control#2) (n=9); or **Sixth Bar**, 5µg of D-ala²-GLP-1 given at t=0, 4 and 8 hrs prior to OGTT (control#3) (n=4). * P<0.05, *** P<0.001 vs. control#1. These results show that our microspheres deliver therapeutic levels of GLP-1 to non-diabetic mice.

Figure 8 is a graph showing basal blood glucose values at the beginning of each OGTT at t=0, 4 and 8 hours in diabetic db/db mice. **Squares**: control mice given no microspheres. **Open circles**: mice given 12.5 mg of D-ala²-GLP-1-microspheres (* P<0.05, n=9). These results show that our microspheres lower basal blood glucose values over an 8 hour period in a model of type II diabetes.

Figures 9A-C are graphs showing basal blood glucose values in a mouse model of type II diabetes (*db/db* mice, which have a leptin receptor mutation). Delta blood glucose levels following repeated OGTT at 0 (FIG. 9A), 4 (FIG. 9B) and 8 (FIG. 9C) hours. Mice were treated at t=0 hrs with; nothing (controls, **diamonds**; n=9); or with orally administered microspheres containing 250µg D-ala²-GLP-1 (**squares**; n=9). These results show that our microspheres cause a downward shift in the OGTT response in diabetic mice.

Figures 10A and B are graphical analysis of the results seen in figure 9 using area under the curve (AUC). **FIG. 10A**: Values expressed as the absolute area under the curve (area under the curve of the values including the basal blood glucose values). **FIG. 10B**: Values expressed as the delta area under the curve (area under the curve of the values independent of the basal blood glucose values). For figures 10A and 10B

- 7 -

the black bars are for control mice and the grey bars are for mice given microspheres containing D-ala²-GLP-1. * P<0.05, *** P<0.001 vs. controls. These results show that our microspheres significantly lower the glycemic response to repeated OGTT in diabetic mice.

5 **Figure 11** shows fluorescent staining of tissue after administration of microspheres containing Dextran-Texas Red. **Row A** tissue from the duodenum; **Row B** tissue from the ileum; **Row C** tissue from the spleen; and **Row D** tissue from the liver. **Column 1** tissues shows light microscopy representative pictures for each tissue (100X).
10 **Column 2** shows the results from mice 2 hours after being fed 250µg of Dextran-Texas Red alone; **Column 3** shows the results from mice 2 hours after being fed Dextran-Texas Red-microspheres; and **Column 4** shows the results from mice 4 hours after being fed Dextran-Texas Red-microspheres. Areas of concentrated fluorescence were found in the duodenum, ileum,
15 spleen and liver of Dextran-Texas Red-microsphere treated mice only, indicating that absorption of the microspheres occurred across the gastrointestinal tract.

DETAILED DESCRIPTION OF THE INVENTION

Microsphere Composition

20 The present invention relates to a novel microsphere composition. In particular, the present inventors have demonstrated that microsphere compositions containing an active agent and a biocompatible oil show an increase in the release rate of the active agent as compared to a microsphere composition without the oil. Consequently, the microsphere
25 composition of the invention provides an improved delivery system for the administration of active agents. The bioactivity of the active agent is increased as compared to the bioactivity in the absence of the microsphere composition.

Broadly stated, the present invention provides a microsphere
30 composition comprising a biocompatible oil and a polymer capable of forming microspheres.

- 8 -

In one embodiment the microsphere composition additionally includes an active agent. Accordingly, the present invention provides a microsphere composition comprising (a) an active agent and (b) a biocompatible oil encapsulated in (c) a microsphere formulation. The
5 microsphere composition is preferably suitable for oral administration.

The microsphere can be composed of any biodegradable polymer that is capable of forming microspheres including, but not limited to, polyesters, polyketals, polyorthoesters, polyanhydrides, polyacetals, polyureas, polycarbonates, polyurethanes, polyamides and combinations
10 thereof. The polymer is preferably in an amount from about 20% to about 79%, more preferably about 30% to about 50%, of the total composition. For oral preparations the polymer should be able to adhere to the intestinal mucosa, be taken up into the systemic circulation and be non-toxic. Preferably, the microspheres are formed from poly-lactide-co-
15 glycolide (PLGA or PLAGA). More preferably, the polymer is poly-lactide-co-glycolide-COOH. The finding that PLGA-COOH microspheres containing an active agent and oil could increase the release of the active agent was surprising as PLGA-COOH microspheres containing active agent without oil are poor releasers of active agents.

20 The biocompatible oil may be any oil that is non-toxic and edible including, but not limited to, olive oil, canola oil, soybean oil, sunflower oil, coconut oil, safflower oil, cotton seed oil, peppermint oil or chili pepper oil. The oil is preferably present in a range from about 20 to about 70%, more preferably about 30% to about 50%, of the total
25 composition. In one embodiment, the oil is olive oil.

The active agent may be any agent which one wishes to administer to a host including, but not limited to, hormones, proteins, peptides, peptide analogs, peptide derivatives, drugs, vaccines, antigens vitamins, carbohydrates or lipids. The active agent is preferably present in
30 an amount from about 1 to about 20%, more preferably about 2 to about 10%, of the total composition. The active agent may optionally be dispersed in a solution (preferably an aqueous solution) prior to the

- 9 -

preparation of the microspheres. In one embodiment, the active agent is glucagon-like peptide-1 (GLP-1), more preferably D-ala²-GLP-1.

In one embodiment of the invention, the microsphere composition comprises: (a) a therapeutic peptide and (b) olive oil in (c) a poly-lactide-co-glycolide microsphere formulation. In a specific embodiment, the microsphere composition comprises (a) a therapeutic peptide in an amount from about 1% to about 20%, preferably 2%, of the composition; (b) olive oil in an amount from about 20% to about 70%, preferably 50%, of the total composition in (c) a PLGA-COOH microsphere formulation in an amount from about 20% to about 79%, preferably 48%, of the total composition.

The present invention also provides a method for preparing a microsphere preparation comprising (a) adding a polymer capable of forming microspheres to a biocompatible oil; (b) adding an active agent to the polymer and oil solution; (c) pouring the mixture into a non-solvent solution under conditions which allow for the spontaneous formation of microspheres containing the biocompatible oil and the active agent. The active agent may optionally be dispersed in a solution (preferably an aqueous solution) prior to the preparation of the microspheres.

Preferably, the polymer is dispersed in methylene chloride prior to adding it to the oil. The active agent is preferably a peptide in an aqueous solution. The non-solvent solution is preferably petroleum ether.

Uses of the Microsphere Compositions

As hereinbefore mentioned, the microsphere compositions of the present invention show an increase in the release rate of the active agent as compared to microspheres compositions that do not contain a biocompatible oil. Accordingly, the present invention provides a use of a microsphere composition according to the invention to deliver an active agent. This aspect includes a method of delivering an active agent to an animal comprising administering an effective amount of a microsphere

- 10 -

composition according to the invention to an animal in need thereof. Preferably, the microsphere composition is administered orally.

The term "effective amount" as used herein means an amount effective, at dosages and for periods of time necessary to achieve
5 the desired result.

The term "animal" as used herein includes all members of the animal kingdom, including humans.

The term "active agent" as used herein means any agent that one would like to administer to a host including all therapeutic,
10 prophylactic and diagnostic agents. Examples of active agents include, but are not limited to, proteins, peptides, peptide analogs, peptide derivatives, hormones, vaccines, antigens, drugs, vitamins, carbohydrates or lipids.

The inventors have shown that delivering active agents such as therapeutic peptides using a microsphere composition of the present
15 invention increases the bioactivity of the active agent as compared to when the active agent is administered without the microsphere composition. Accordingly, the present invention also provides use of a microsphere composition according to the invention to increase the bioactivity of an active agent. This aspect includes a method of increasing
20 the bioactivity of an active agent comprising administering a microsphere composition according to the present invention to an animal in need thereof.

In a specific embodiment of the invention, the active agent is one which is useful as a therapeutic agent for the treatment of diabetes
25 such as insulin or a GLP. In a preferred embodiment, the active agent is the peptide GLP-1. Accordingly, the present invention also provides a use of a microsphere composition of the invention to treat diabetes. This aspect includes a method of treating diabetes comprising administering a microsphere composition comprising GLP-1 to an animal in need thereof.
30 The composition is preferably administered orally. The term "GLP-1" as used herein includes all analogs and derivatives of GLP-1 such as D-ala²-GLP-1.

- 11 -

In particular, the present inventors have encapsulated an analog of GLP-1, D-ala²-GLP-1 in microspheres made of 50% olive oil and 48% PLGA-COOH which were given to diabetic mice. The results, discussed in detail in the examples, demonstrate that the microspheres
5 were effective in delivering therapeutic levels of GLP-1 over a ten hour period, thereby reducing both basal blood glucose levels and the glycemic response to repeated OGTT. As a result, the microspheres of the present invention are useful in the treatment of diabetes as patients could rely on a single dose of the microsphere composition to maintain therapeutic
10 levels of GLP-1 throughout the day.

The following non-limiting examples are illustrative of the present invention:

EXAMPLES

Materials and Methods

15 Petroleum ether and acetonitrile were obtained from Fisher Scientific Ltd (Toronto, ON, Canada), gentamicin sulfate, methylene chloride, KOH, acidic boron trifluoride, o-phosphoric acid and Triethylamine (TEA) from Sigma Chemicals (St. Louis, MO), Human placental Dipeptidylpeptidase IV (DP-IV) from Calbiochem-Novobiochem
20 (La Jolla, CA), poly(DL-lactide-co-glycolide- COOH; 50/50) from Birmingham Polymers Inc. (PLGA-COOH, M_w ~11.5 kD; Birmingham, AL), glucagon from Eli Lilly Canada Inc (Toronto, ON, Canada), diprotin A from Calbiochem (San Diego, CA), GLP-1(7-36)amide from Bachem California Inc (Torrance, CA), and Dextran-Texas Red, 3000 MW, lysine
25 fixable from Molecular Probes, Inc (Eugene, OR). D-Ala²-GLP-1 and hexenoyl-His¹-GLP-1 were a kind gift from Dr. St. Pierre (UQAM, Montreal, QC, Canada). Spurr's Resin Kit was purchased from Marivac LTD (Halifax, NS), Cryomatrix from Shandon Inc. (Pittsburgh, PA), 3-O-Methyl-D-[1-3H] glucose from Amersham Life Science (Elk Grove, IL),
30 and Olive Oil from Gallo (100% pure olive oil, from Unico Inc., Concord, ON). Triheptadecanoin from Nu-Chek Prep Inc. (Elysian, MN). EMLA Cream (2.5% Prilocaine and 2.5% lidocaine) and Xylocaine (5%, lidocaine

- 12 -

ointment, USP) from Astra Pharma Inc (Mississauga, ON), and Scintillation fluid (Ultima Gold MV) from Packard Instruments Inc. (Meriden, CT).

In vitro analysis of D-ala²-GLP-1 Degradation by DP-IV

5 Incubation of 0.125 mU of DP-IV (specific activity = 5000 mU/mg protein) with either 33µg GLP-1(7-36)amide or 33µg D-ala²-GLP-1 for 3, 8 or 24 hours was performed at 37°C in phosphate buffered saline (PBS). The reaction was quenched by adding 200µg of Diprotin A. The change in the elution position of the degradation product was compared to
10 the undegraded peptide and to an internal standard of ¹²⁵I-GLP-1 using reversed-phase high-performance liquid chromatography (HPLC). The column was a µBondapak C₁₈ column (3.9X300 mm) (Waters Associates., Milford, MA). The gradient ran from 45% to 85% of solution B (40% solution A and 60% acetonitrile; solution A: 0.1% o-phosphoric acid and
15 0.3% triethylamine) over 55 minutes.

Polymer preparation

Polymers were prepared using a modification of the microencapsulation by phase-inversion method described by Mathiowitz *et al* (15). In brief, 250µg of peptide and different amounts of albumin
20 (depending on the percent loading desired) were dissolved in 25µl of ddH₂O in a glass tube. In a second glass tube, 0-10µl of olive oil (density 0.91 g/mL) was added (depending on the percent of the total weight required). In a third glass tube, a stock suspension of PLGA-COOH polymers was prepared (12.5 mg/ml in methylene chloride). 500µl of the
25 PLGA-COOH solution was then added to the glass tube containing the olive oil, vortexed, and added to the 25µl ddH₂O. This was vortexed for 5 seconds and then rapidly poured into 50 mL of unstirred petroleum ether (methylene chloride:petroleum ether ratio of 1:100), resulting in the spontaneous formation of PLGA-COOH microspheres. This was allowed

- 13 -

to air-dry in a fumehood for approximately 3 hours and then the microspheres were then harvested.

Size Analysis

Transmission Electron Microscopy (TEM): Microspheres were prepared
5 with no peptide or olive oil and then infiltrated with Spurr's Resin and
cured for 2 hours at 65°C. 5-10µm sections were then prepared and
observed at 75 kV.

Particle size determination by Dynamic Light Scattering (DLS): A Nicomp
370/Autodilute Submicron Particle Sizer (Pacific Scientific, Instruments
10 Div., Silver Springs, MD) was used for the analysis of 1 mg of probe
sonicated or unsonicated D-ala²-GLP-1-Olive Oil-PLGA-COOH
microspheres. The light source in the Nicomp was a HeNe laser beam at
632.8-nm, and the angle of detection was 90°. All analysis were done using
a Gaussian analysis method.

15 Analysis of Oil Content

Teflon-silanized coated glass tubes were used to prevent the
fatty acids from sticking to the tubes. Three samples of olive oil alone or
10 mg of PLGA-COOH microspheres with no olive oil, with olive oil or
with olive oil and D-ala²-GLP-1 were analyzed using this method. The
20 triglycerides were broken down using 1 M KOH in methanol under N₂ gas
at 90°C for 2 hours. BF₃ (acidic boron trifluoride in methanol) was then
used as a catalyst for methylation of the FFA to give FFA-methyl esters. A
Hewlett Packard 5890A Gas Chromatograph was used to separate the
different types free fatty acids (FFA). To aid in the determination of the
25 amounts of each type of FFA in olive oil an internal standard of
triheptadecanoin was added to each sample. Using the amounts of FFA in
each sample and knowing the composition of olive oil, the amount of
olive oil in the microspheres was determined in mg of olive oil/mg of
microspheres (note olive oil alone was analyzed in varying concentration
30 (3,5 and 7µl of olive oil) to produce a standard curve for comparison).

- 14 -

In vitro analysis of Peptide Release

A known amount of polymer was weighed into a polypropylene tube and 10 ml of PBS (pH 7.4) with 0.05 mg/ml of gentamicin sulfate. The tube was shaken vigorously for 20 seconds and then centrifuged for 5 minutes at 1300Xg. A sample of the PBS-Gentamicin was collected, then the tube was manually shaken for 20 seconds to resuspend the polymer, after which the suspension was incubated at 37°C. Additional samples were taken every hour for the first 9 hours and then after 24, 32, 48, 56, 72 and 80 hours.

10 Oral Glucose Tolerance Tests (OGTT)

Female CD1 mice (6-8 weeks old) obtained from Charles River Canada (Montreal, QC, Canada), or female db/+ or db/db mice (7-11 weeks old) obtained from Jackson Laboratories (Bar Harbor, ME, USA) were used for all experiments. Mice were housed under a light/dark cycle of 12 hours, and were fasted for 16-17 hours prior to the day of experimentation. All experiments were initiated between 0900 and 1000. Mice were given 1.5 mg of glucose per gram of body weight orally through a gastric gavage tube (18 or 22 gauge gavage needle) and blood was collected from a tail vein at 0, 10, 20, 30, 60, 90, 120 minutes. Blood glucose levels were measured with a One Touch Glucose meter (Lifescan Canada LTD, Burnaby, BC, Canada). At t=0 minutes either; polymers were administered orally with the glucose using a 22G gavage needle, or intraperitoneally (*ip*) using a 25G5/8 needle (note: some of the polymer preparations were probe-sonicated for 4-8 seconds at a 16 kc/s with a peak-to-peak amplitude of 5-7 m, to allow for smooth delivery), or 5µg of D-ala²-GLP-1 was delivered by subcutaneous (*sc*) or *ip* injection with 25G5/8 needle. At the end of each oral glucose tolerance test (OGTT), EMLA Cream or Xylocaine was applied to the tip of the tail. In some mice, OGTT's were repeated at t=4 and 8 hours.

30 Determination of Gastric Emptying

Gastric emptying measurements were done in CD1 mice along with an OGTT using 3-O-Methyl-D-[1-3H] glucose similar to a

- 15 -

method described by Gedulin and Young (29). The protocol is the same as above for the OGTT except 5 μ Ci of 3-O-Methyl-D-[1-3H] glucose was added to the glucose solution given to the mice. Plasma blood samples at 0, 10, 20, 30, 60, 90 and 120 minutes were taken to measure cpm.

5 3-O-Methyl-D-[1-3H] glucose has been shown to be a good measure of gastric emptying (29). Thus, after determination of the blood glucose concentrations, an additional 4-5 drops of blood was obtained from the mice and placed into a microhematocrit capillary tube, sealed at the end with critseal and then centrifuged to collect 5 μ l of plasma. Which was

10 added to plasma scintillation fluid and counted on a -counter.

Route of Absorption and Targets Organs of the Microspheres

Dextran-Texas Red was encapsulated into PLGA-COOH microspheres with olive oil as describe above for the encapsulation of peptides. Dextran-Texas Red, 3000 MW, was chosen because it had a

15 similar MW to that of GLP-1. These microspheres were then given to CD1 mice by oral gavage. Tissues (stomach, duodenum, ileum, large intestine, cecum, kidney, liver and spleen) were collected at 2 or 4 hours after administration and frozen at -70°C in cryomatrix. After 12-14 hours, fresh unstained tissue sections of 15-20 μ m in size were prepared using a cryostat.

20 Tissue section were viewed immediately after cutting using a confocal microscope with tungsten mercury lamp (filter wave length at 595 nm).

Radioimmunoassays (RIAs)

RIAs for immunoreactive glucagon (IRG) and immunoreactive GLP-1(7-36)amide were carried out (30) using antiserum

25 04A (Dr. R.H. Unger, Dallas, TX), which cross-reacts with the free C-terminal end of glucagon, and antiserum GLP-1(7-36)amide (Affinity Research, Nottingham, UK), which detects C-terminally amidated forms of GLP-1, respectively. Plasma was prepared for GLP-1 RIA by reversed-phase extraction on a C18 SepPak (Waters Associates, Milford, MA) and extracts

30 were dried *in vacuo* prior to assay (30,31).

- 16 -

Statistics

Statistical significance was assessed by ANOVA using n-1 custom hypotheses tests, or by Tukey's studentized range test, as appropriate, using a Statistical Analysis System program (SAS Institute, Cary, NC). All data are expressed as the mean \pm SEM.

RESULTS

Example 1: Increasing GLP-1 Duration of Action

(A) *In vitro*:

Reversed-phase high-performance liquid chromatography (HPLC) was used to compare the degradation of D-ala²-GLP-1 to that of native GLP-1 by DP-IV *in vitro*. HPLC analysis of D-ala²-GLP-1 showed no DP-IV cleavage over a 24 hour period whereas native GLP-1 was cleaved within 3 hours when incubated with DP-IV *in vitro* ($P < 0.05$, $n = 3$). (The results are shown in Figure 1.)

(B) *In vivo*:

To determine whether D-ala²-GLP-1 maintained its biological activities *in vivo*, mice were given a *sc* injection of saline or 10 μ g of native GLP-1 or D-ala²-GLP-1, and their response to an oral glucose tolerance test (OGTT) was determined. Native GLP-1 significantly reduced the glycemic area under the curve over a period of 2 hours (AUC) in comparison to saline (from 337 ± 80 to 209 ± 29 mM*120 minutes; $P < 0.05$, $n = 6$), and D-ala²-GLP-1 further reduced the AUC significantly in comparison to both saline and native GLP-1 (-552 mM*120 minutes; $P < 0.001$, $n = 6$). (The results are shown in Figure 2.) Thus, this new analog of GLP-1 exhibits enhanced biological activity *in vivo* as compared to native GLP-1, likely because of its ability to resist DP-IV inactivation.

Example 2

(2A) *Designing an Oral Delivery System for D-ala²-GLP-1*

The preferred release pattern for the delivery of GLP-1 to type II diabetics would be over a 9-12 hour period because patients could rely on a single dose to maintain therapeutic levels of GLP-1 throughout the day. PLGA-COOH is an excellent polymer for the formation of microspheres

- 17 -

because it adheres to the intestinal mucosa of the gastrointestinal tract due to its -COOH end groups (15,32-34). PLGA has also been shown to be taken up taken up into the systemic circulation (15,19), and its degradation products are non-toxic (16). However, the degradation rate of PLGA is very
5 slow, and it is therefore not considered to be useful in the delivery of therapeutic levels of compounds (35). Consistent with these findings, initial studies using PLGA-COOH microspheres alone showed that the release of encapsulated glucagon was near background levels over 9 hours (n=2; Figure 3), and did not increase even after 408 hours of incubation
10 (data not shown).

In an attempt to increase the rate of release of peptide from PLGA-COOH microspheres, we tested the effects of incorporating albumin. Using a range of concentrations to obtain up to 60% percent of the total weight of the microsphere with albumin, the best release obtained was
15 only 9.8% of the total glucagon (250µg of peptide/ 12.5 mg of microspheres) encapsulated within the microspheres over a 9 hour period (Figure 3, only 18% albumin shown; n=2). In a separate series of studies, olive oil was also tested for effects on the release of peptide from PLGA-COOH microspheres. Olive oil is non-toxic, and is soluble in methylene chloride,
20 but not in petroleum ether, all of which are important considerations for the preparation of our microspheres. The addition of olive oil consisting of 30% to 50% percent of the total weight of the microspheres increased the release of encapsulated glucagon to 43.1% (n=1) and 68.4% (n=2) of total peptide over a 9 hour period, respectively (Figure 3).

25 The 50% olive oil-PLGA-COOH microsphere preparation was selected for further studies using the D-ala²-GLP-1 and hexenoyl-His¹-GLP-1 analogs of GLP-1. In preliminary studies, we determined that this new analog, D-ala²-GLP-1, is detected in our GLP-1 assay in a similar fashion to that of wild-type GLP-1 (data not shown).
30 When encapsulated within PLGA-COOH microspheres containing 50% olive oil, the release of D-ala²-GLP-1 and hexenoyl-His¹-GLP-1 reached 10421% (n=4) and 89.2% (n=2) of the total peptide within 9 hours,

- 18 -

respectively (Figure 3). The release profiles for PLGA-COOH microspheres containing olive oil and either glucagon (n=2) or D-ala²-GLP-1 (n=4) demonstrated an initial burst phase at about t=1 hour, followed by a decline (likely due to loss of peptide *via* adsorption to the test tube and to the microsphere surface), a second release phase with a peak at t=7-9 hours, and then a further decline over the ensuing 48 hours (Figure 4). A similar profile was observed for hexenoyl-His¹-GLP-1, with the only apparent difference being the absence of the 'decline phases'. We decided that the microspheres consisting of 50% olive oil- 48% PLGA-COOH- 2% peptide were the preferred composition for *in vivo* studies.

Each of the peptides were likely encapsulated within these 50% olive oil-PLGA-COOH microsphere preparation because if you encapsulate a water soluble dye (Dextran-Texas Red; purple color) into these microspheres and then place these microspheres into water, there was no or very likely change in the color of the water after the microspheres had settled to the bottom of the tube. These results were consistent even after the microspheres were probe sonicated for 8 seconds.

(2B) Size of the microspheres

Two methods were used to determine the size of the microspheres, both of which gave similar results. The first method was transmission electron microscopy (TEM). These experiments were carried out with microspheres without any peptide or olive oil, giving a result of 0.96 μ m in size (Figure 5; n=3). We also used a Dynamic Light Scattering (DLS) method for determining particle size (36,37). Using microspheres containing olive oil and D-ala²-GLP-1, which were either sonicated or unsonicated (Table 1; n=4). The size of the microspheres were 1.01 μ m for the sonicated and 2.32 μ m for the unsonicated. These results suggested to us that, because our microspheres were <5 μ m in size, they are a suitable size for absorption across the gastrointestinal tract (38).

(2C) Olive Oil Content of the Microspheres

These experiments were performed on microspheres made of PLGA-COOH with no peptide or olive oil; with olive oil or with olive oil

- 19 -

and peptide. Microspheres made of PLGA-COOH alone had no measurable amount of olive oil; those made of PLGA-COOH and olive oil had 0.22 ± 0.07 mg of olive oil/ mg of microsphere and those made of PLGA-COOH with olive oil and D-ala²-GLP-1 had 0.30 ± 0.02 mg of olive oil/ mg of microsphere (figure 6) as compared to the 0.50 mg of olive oil/ mg of microsphere that was added during the microsphere preparation. This data suggests that about 60% of the olive oil added to the preparation was incorporated into the microspheres.

Example 3

10 (3A) Effects of D-ala²-GLP-1-microspheres *in vivo*

When 2.5 mg D-ala²-GLP-1-microspheres (equivalent to 50µg of peptide at 2% loading) were injected *ip* into non-diabetic CD1 mice followed by repeated OGTT at 0, 4 and 8 hours, the glycemic area under the curve (AUC) in response to the repeated OGTT was significantly reduced as compared to controls at 0, 4 and 8 hours (from 346 ± 53 to 93 ± 59 mM*120 minutes, $P < 0.001$ at 0 hours; from 424 ± 24 to 219 ± 50 mM*120 minutes, $P < 0.001$ at 4 hours; from 461 ± 29 to 282 ± 49 mM*120 minutes, $P < 0.001$ at 8 hours; n=12 and 6 respectively) (figure 7). When 5µg of D-ala²-GLP-1 was given alone by *ip* injection at t=0 hours, there was a significant difference as compared to controls only at t=0 hours but not at any of the other time points (from 346 ± 53 to 161 ± 67 mM*120 minutes, $P < 0.001$ at 0 hours; n=6). This suggested to us that the peptide alone lost its ability to affect the glycemic response within 4 hours and that when the microspheres are given by an *ip* injection, bioactive GLP-1 levels are maintained over an 10 hour period.

When 12.5 mg D-ala²-GLP-1-microspheres (2% loading; equivalent to 250µg of peptide) were given orally to mice (non-diabetic CD1 mice) (at t=0 hours) followed by repeated OGTT at 0, 4 and 8 hours, the glycemic AUC was significantly reduced as compared to controls at the 4 and 8 hour time points (from 424 ± 24 to 247 ± 50 mM *120 minutes, $P < 0.001$ at 4 hours; and from 461 ± 29 to 371 ± 53 mM *120 minutes, $P < 0.05$ at 8 hours; n=9) (figure 7). This demonstrated that our microsphere preparation was

- 20 -

effective in delivering bioactive levels of GLP-1 orally to mice over a 10 hour period.

In an attempt to control for the amount of peptide given within the microspheres, 250 μ g of D-ala²-GLP-1 was given orally to mice. The glycemic AUC was not significantly affected as compared to controls at any of the time points studied (295 \pm 54 mM *120 minutes, at 0 hours; 340 \pm 28 mM *120 minutes, at 4 hours; 514 \pm 38 mM *120 minutes, at 8 hours; n=9) (figure 7). Another control to predict the approximate amount of peptide present at each time point was carried out by giving an *ip* injection of 5 μ g of D-ala²-GLP-1 just before each OGTT (one injection at each of t=0, 4 and 8 hours). The glycemic AUC was significantly reduced as compared to controls at all of the time points studied (from 346 \pm 53 to 198 \pm 56 mM*120 minutes, P<0.001 at 0 hours; from 424 \pm 24 to 128 \pm 37 mM*120 minutes, P<0.001 at 4 hours; from 461 \pm 29 to 170 \pm 32 mM*120 minutes, P<0.001 at 8 hours; n=4) (figure 7). These results are therefore similar to those found for the administration of 12.5 mg of D-ala²-GLP-1-microspheres (containing 250 μ g of peptide), suggesting that approximately 1-2% of the peptide was available at the 4 and 8 hour OGTT.

(3B) Effects of D-ala²-GLP-1-microspheres on Gastric emptying

High concentrations of GLP-1 have been reported to affect gastric emptying in humans (39,40) as well as in rodents (41). Therefore to test whether this is the case with the D-ala²-GLP-1-microspheres, we added 5 μ Ci 3-O-Methyl-D-[1-3H] glucose to the glucose given to control CD1 mice, or mice given an *ip* injection of 5 μ g of D-ala²-GLP-1, oral microspheres or the mice given 250 μ g of oral D-ala²-GLP-1, for OGTT at either t=0, 4 or 8 hours. The results showed that there was no significant effect of the microspheres, or any other treatment, on gastric emptying in these mice at all time points (data not shown).

(3C) Effects of D-ala²-GLP-1-microspheres in a Model of Type Diabetes

When D-ala²-GLP-1-microspheres were given orally to diabetic *db/db* mice (at 0 hours), followed by repeated OGTT at 0, 4 and 8

- 21 -

hours, the basal blood glucose values were reduced at 4 hours (from 13 ± 1.4 to 10 ± 1.4 mM) and significantly reduced at 8 hours (from 12 ± 1.1 to 80 ± 9 mM, $P < 0.05$, $n=6$) in comparison to controls, *db/db* mice given no microspheres (figure 8). The OGTT response at $t=0$ hours for both mice
5 treated with the D-ala²-GLP-1-microspheres and the controls were not distinguishable from each other but at $t=4$ and 8 hours the OGTT curves were drastically different from each other with the diabetic mice receiving D-ala²-GLP-1-microspheres curve being shifted downward (figure 9). In addition, the absolute glycemic AUC (AUC calculated including basal
10 blood glucose values) was reduced significantly as compared to controls at 4 and 8 hours time points (from 2589 ± 105 to 1921 ± 138 mM*120 min, at 4 hour, $P < 0.001$; and from 2460 ± 152 to 1835 ± 88 mM*120 min, at 8 hour, $P < 0.001$; $n=6$) (figure 10A). Also, the delta glycemic AUC (AUC independent of the initial basal blood glucose value) was also significantly
15 reduced in comparison to controls at 4 hour time point (from 1000 ± 140 to 714 ± 49 mM*120 min, $P < 0.05$; $n=6$) (figure 10B). These findings demonstrate that, in diabetic mice, D-ala²-GLP-1 encapsulated into PLGA-COOH-microspheres is effective in delivering therapeutic levels of GLP-1 orally over an 10 hour period, thereby reducing both basal and the
20 glycemic response to repeated OGTT.

Example 4: Route of Absorption and Targets Organs of the Microspheres

Dextran-Texas Red was encapsulated into PLGA-COOH microspheres with olive oil and then given orally to CD1 mice. No fluorescence was seen in mice treated with microspheres containing no
25 Dextran-Texas Red. Diffuse fluorescence was found in the duodenum, ileum, liver, kidney and the spleen of the mice given $250 \mu\text{g}$ of Dextran-Texas Red alone orally and in mice given microspheres containing Dextran-Texas Red 2 and 4 hours after administration. However, there was significantly more intense fluorescence seen in the
30 microspheres treated mice as compared to the $250 \mu\text{g}$ of Dextran-Texas Red alone (figure 11). These results suggested that, although diffuse fluorescence was seen in both Dextran-Texas Red-microspheres and in

- 22 -

mice treated with Dextran-Texas Red alone, the concentrated fluorescence seen in the microsphere treated mice was likely a result of the absorption of the microspheres in the duodenum and ileum after which ending up in the liver, kidney and spleen.

5 DISCUSSION

The results of the present study indicate that encapsulation of GLP-1 in microspheres composed of 48% PLGA-COOH, 50% olive oil and 2% peptide permits delivery of bioactive GLP-1 through the oral route in mice.

10 The major contributor to the relatively short half-life of 0.9 minutes for GLP-1 (25) is the enzyme Dipeptidyl-Peptidase-IV (DP-IV), which cleaves the first two amino acids (His¹-ala²) from the N-terminus of GLP-1 and thus inactivating the peptide (27,46). To overcome this short half-life, Dr. Serge St. Pierre from the University of Quebec in Montreal,
15 synthesized an analog of GLP-1 that was designed to be DP-IV resistant. We have shown that this novel GLP-1 analog, D-ala²-GLP-1, is resistant to DP-IV cleavage over a 24 hour period *in vitro* and maintains its biological activities *in vivo*. These data suggest that this peptide can potentially be used in the treatment of type II diabetes. However, even with this
20 resistance to DP-IV cleavage the biological activities of D-ala²-GLP-1 were lost 4 hours after an *ip* administration (figure 7), thus still necessitating the need for repeated injections of the peptide if it is to be used as a treatment of type II diabetes.

 Therefore because of possible non-compliance with a regimen
25 of repeated GLP-1 injections, we have designed a novel oral delivery system for this peptide. Although a number of investigators have utilized PLGA and related polymers for oral peptide delivery (11,15,19), several novel aspects of the present study warrant discussion. First, no previous studies have reported on the use of PLGA-COOH as the base polymer for
30 microsphere preparation. The modification of adding a -COOH end group to these polymers was done to decrease the passage of microspheres through the gastrointestinal tract and thus increases there chance of being

- 23 -

absorbed (32-34). However, as we and others (47,48) have demonstrated in our *in vitro* studies, the use of PLGA or PLGA-COOH alone did not permit release of the test peptide within a time frame that is reasonable for peptide therapeutics.

5 Thus, in an attempt to increase the rate of release of peptide from these microspheres, the PLGA-COOH was combined with other more soluble biocompatible compounds, including albumin and olive oil. Albumin had only a marginal effect on increasing the rate of release of peptide. The addition of increasing concentrations of olive oil on the
10 other hand, up to 50% of the total weight of the microspheres, clearly increased the ability of peptide to be released from the microspheres, such that approximately 70-100% of the peptide was consistently recovered within 9 hours of incubation *in vitro*, regardless of the peptide being tested. Interestingly, despite the excellent recovery of peptide during these
15 incubations, microspheres were still clearly visible, even after 17 days of incubation. These findings suggest that the major mechanism of release of peptide from these microspheres is diffusion, rather than through degradation and/or bulk erosion, as reported for other polymer preparations (49,50).

20 As no other studies had previously reported on the use of olive oil in their polymer preparation or any other commercially available ingestable oils for that matter, these novel findings clearly require further testing. There are two studies to date that have used oleic acid, a major constituent of olive oil (70%), to affect polymer function. One study
25 attempted to use oleic acid to enhance the uptake of polystyrene microparticles into lymph of rats (51). In this study they found that microparticles in a solution of 6% oleic acid did not enhance the absorption of the polystyrene microparticles and in fact decreased their absorption as compared to saline in a closed intestinal-loop model. What
30 is interesting is that lecithin (another lipid delivery vehicle) did marginally enhance the absorption of the polystyrene microparticles in this model suggesting that this lipid could also be used as a substitute for

- 24 -

olive oil in our experiments. In another study they used oleic acid, and other low molecular weight compounds, to enhance the degradation rate of poly(-caprolactone) and PLGA (47) by applying it to the surface of the polymer and then measured the degradation products. They found that
5 the rate of PLGA hydrolysis was increased when oleic acid was applied to the surface of the polymer, suggesting a change in the intrinsic reactivity of the glycolate linkage in PLGA.

What is unique about our experiments in comparison to these studies using oleic acid is that we have used olive oil as an integral
10 component of our microspheres as opposed to a mode of delivery or as a topical application. Support for olive oil being part of our microspheres comes from our studies that our microspheres have olive oil incorporated into the microspheres using gas chromatography. Also, in view of the study (47) showing that oleic acid increases the rate of degradation of
15 PLGA, it is likely that the addition of olive oil increased the rate of degradation of PLGA-COOH-microspheres, from the inside out, thus allowing for an increase in the release of peptide such that there was a nearly complete recovery of the total amount of peptide added (as seen in our *in vitro* release studies).

20 In general, microspheres that are $<5\mu\text{m}$ in size have been suggested to be suitable for absorption across the gastrointestinal tract (19,38,52,53). There are four proposed sites of absorption of microspheres which include the villus tips, intestinal macrophages, enterocytes and Peyer's patches (38). The mechanism of absorption at each of these sites
25 dictates the size of particles that can be absorbed. The proposed mechanism of absorption across villus tips is persorption which would allow for particles that are $5\text{-}150\mu\text{m}$ in size to be absorbed, intestinal macrophages can absorb $1\mu\text{m}$ particles by phagocytosis, enterocytes can absorb $<200\text{ nm}$ particles by endocytosis and Peyer's patches can absorb
30 $<10\mu\text{m}$ particles by transparacellular means. Although all of these sites likely play role in absorption, the major site of absorption of all

- 25 -

microparticles has been suggested to be the Peyer's patches (54,55). Along these lines, the main site of PLGA microspheres absorption in the size range of 1-5 μ m has been shown to be the Peyer's patches (19). After absorption of the PLGA-microspheres they have been found in the lymph
5 nodes, spleen, kidneys and liver. The microspheres that we produced were about 1 μ m in size, suggesting to us that they were a suitable size for absorption across the gastrointestinal tract. In addition, the sites where they were found included the duodenum, ileum, spleen, kidney and liver at 2 and 4 hours after administration, as determined by encapsulating
10 dextran-Texas Red into our microspheres.

In vivo studies with D-ala²-GLP-1-microspheres clearly indicated that the peptide was release into the circulation of the mice and retained its biological activity when delivered through the *ip* and oral routes of administration. An *ip* injection of D-ala²-GLP-1-microspheres
15 permitted the delivery of bioactive levels of peptide that results in a significant reduction of the area under the curve in response to OGTT at t=0, 4 and 8 hours. The time course of action for these effects differed markedly from that of non-encapsulated peptide, such that a much more prolonged duration of action was observed for the
20 D-ala²-GLP-1-microspheres (for a least 10 hours). The effectiveness of this peptide over the entire 10 hour period tested is ideal for the delivery of a therapeutic peptide that is required over a prolonged period of time.

When we gave our D-ala²-GLP-1 alone to non-diabetic mice we found that the duration of action of a single dose of *sc/ip* D-ala²-GLP-1
25 is extremely short (<4 hours), orally administrated D-ala²-GLP-1 (250 μ g) is biologically inactive. When the D-ala²-GLP-1-microspheres were given orally it permitted the delivery of bioactive peptide that resulted in a significant reduction of the area under the curve in response to OGTT at t=4 and 8 hours but not at t=0 hours. If the major site of microsphere
30 absorption is by the Peyer's patches then for an effect to be seen one must wait until the microsphere get to the ileum where the majority of the Peyer's patches are located (56-61). The amount of biologically active

- 26 -

peptide at t=4 hours in mice treated with oral microspheres containing a total of 250 μ g of D-ala²-GLP-1 was approximately 5 μ g of peptide (determined by comparing the response of oral microspheres at t=4 hours to a 5 μ g *ip* injection given at t=4 hours). Therefore, in these mice our
5 microsphere preparation permits oral delivery of therapeutic levels of peptide over an 10 hour period equivalent to repeated injections of 5 μ g of peptide (1-2% of the total peptide). This low bioavailability may be due to a slow continuous release mechanism. It is possible that 1% of the total peptide absorbed is released per hour. This is assuming though, that 100%
10 of the microspheres are absorbed. But this is not likely the case because it has been shown previously that only about 12% of PLGA microspheres in the 1-5m μ size range are absorbed across the gastrointestinal tract (19).

D-ala²-GLP-1-microspheres were also given to a mouse model of type II diabetes to determine whether or not therapeutic levels of GLP-1
15 can be delivered orally in diabetes. The mouse model we chose to use was the *db/db* mouse which have a leptin receptor mutation that inactivates the receptor. This mutation results in the mice being hyperphagic, hyperglycemic, hyperinsulinemic and obese (62-64). The late onset of hyperglycemia and hyperinsulinemia in these mice is a similar
20 characteristic found in type II diabetes (63). We found that there was no difference seen between control mice and mice treated with D-ala²-GLP-1-microspheres at t=0 hrs, as expected, however, the response to orally administered microspheres at t=4 and 8 hours was a downward shift in both basal and stimulated glycemia as compared to control mice.
25 Therefore in addition to being able to deliver orally D-ala²-GLP-1 to non-diabetic mice, we are also able to orally delivery therapeutic levels of peptide over a 10 hour period in a diabetic model of type II diabetes. These results suggest that this technique for orally delivery of peptides may be useful in the treatment of type II diabetes and as well as other disorders
30 requiring the continuous presence of peptide.

- 27 -

In conclusion, the results of the present study demonstrate that oral delivery of therapeutic peptides can be accomplished through a novel approach to encapsulate peptides within biocompatible microspheres containing a biocompatible oil. The approach is clearly
5 feasible for delivery of a wide variety of bioactive peptides and possible other compounds. Furthermore, one skilled in the art will appreciate that the rate of peptide release could be modified by altering the percent composition of the oil in the microspheres. Also, additional types of ingestable oils may be used to further adjust the polymer preparation to
10 increase the absorption of the microspheres. Another possibility may be to conjugate molecules to our microspheres that can actively work to increase the absorption of the microsphere preparation. Therefore, with the ability to modify the release kinetics as well as with some minor modification to improve the total amount of microspheres absorbed, this
15 method will be extremely effective in orally delivering therapeutic levels of active agents such as peptides.

While the present invention has been described with reference to what are presently considered to be the preferred examples, it is to be understood that the invention is not limited to the disclosed
20 examples. To the contrary, the invention is intended to cover various modifications and equivalent arrangements included within the spirit and scope of the appended claims.

All publications, patents and patent applications are herein incorporated by reference in their entirety to the same extent as if each
25 individual publication, patent or patent application was specifically and individually indicated to be incorporated by reference in its entirety.

- 28 -

TABLE 1

Preparation	Average Size (μm)	Standard Deviation (μm)
Sonicated Polymers	1.00	1.02
Non-Sonicated Polymers	2.30	2.06

Analysis of the size of the microspheres containing D-ala²-GLP-1 using a Dynamic Light Scattering (DLS) method for determining particle size. The microspheres used for these experiments contained olive oil and D-ala²-GLP-1 and were either sonicated or unsonicated (n=4). Analysis was performed using Gaussian analysis. These results show that our sonicated microspheres are about 1 μm in size, therefore these were used in all subsequent studies *in vivo*.

- 29 -

FULL CITATIONS FOR REFERENCES REFERRED TO IN THE
SPECIFICATION

1. Gutniak MK, Larsson H, Heiber SJ, Juneskans OT, Holst JJ,
Ahrén B 1996 Potential therapeutic level of glucagon-like peptide I
5 achieved in humans by a buccal tablet. Diabetes Care 19:843-848
2. Gutniak MK, Larsson H, Heiber SJ, Juneskans OT, Holst JJ,
Ahrén B 1997 Potential therapeutic levels of glucagon-like peptide I
achieved in humans by a buccal tablet. Diabetes Care 20:1874-1879
3. Sayani AP, Chien YW 1996 Systemic delivery of peptides and
10 proteins across absorptive mucosae. Crit Rev Ther Drug Carrier Syst
13:85-184
4. Pereswetoff-Morath L 1998 Microspheres as nasal drug delivery
systems. Advanced Drug Delivery Reviews 29:185-194
5. Critchley H, Davis SS, Farraj NF, Illum L 1994 Nasal absorption
15 of desmopressin in rats and sheep. Effects of a bioadhesive microsphere
delivery system. J Pharm Pharmacol 46:651-656
6. Henningfield JE 1995 Nicotine medications for smoking
cessation. N Engl J Med 333:1196-1203
7. Mitra A. Ophthalmic drug delivery systems. New York: Marcel
20 Dekker, 1993:223-262.
8. Letterie GS, Coddington CC, Collins RL, Merriam GR 1996
Ovulation induction using s.c. pulsatile gonadotrophin-releasing
hormone: effectiveness of different pulse frequencies. Human
Reproduction 11:19-22

- 30 -

9. Rachman J, Barrow BA, Levy JC, Turner RC 1997 Near-normalisation of diurnal glucose concentrations by continuous administration of glucagon-like peptide-1 (GLP-1) in subjects with NIDDM. *Diabetologia* 40:205-211
- 5 10. Ishida M, Machida Y, Nambu N, Nagai T 1981 New mucosal dosage form of insulin. *Chem Pharm Bull* 29:810-816
11. Wearley LL 1991 Recent progress in protein and peptide delivery by noninvasive routes. *Crit Rev Ther Drug Carrier Syst* 8:331-394
12. Banga AK, Chien YW 1988 Systemic delivery of therapeutic
10 peptides and proteins. *Int J Pharm* 48:15-50
13. McNally PG, Jowett NI, Kurinczuk JJ, Peck RW, Hearnshaw JR 1988 Lipohypertrophy and lipoatrophy complicating treatment with highly purified bovine and porcine insulins. *Postgraduate Medical Journal* 64:850-853
- 15 14. Hermens WAJJ, Merkus FWHM 1988 The influence of drugs on nasal ciliary movement. *Pharm Res* 4:445-449
15. Mathiowitz E, Jacob JS, Jong YS, Carino GP, Chickering DE, Chaturvedi P, Santos CA, Vijayaraghavan K, Montgomery S, Bassett M, Morrell C 1997 Biologically erodable microspheres as potential oral drug
20 delivery systems. *Nature* 386:410-414
16. Ignatius AA, Claes LE 1996 *In vitro* biocompatibility of bioresorbable polymers: poly(L, DL-lactide) and poly(L-lactide-co-glycolide). *Biomaterials* 17:831-839

- 31 -

17. Kreuter J 1996 Nanoparticles and microparticles for drug and vaccine delivery. *J Anat* 189:503-505

18. Chickering DE, 3rd, Harris WP, Mathiowitz E 1995 A microtensiometer for the analysis of bioadhesive microspheres. *Biomedical Instrumentation & Technology* 29:501-512

19. Damge C, Aprahamian M, Marchais H, Benoit JP, Pinget M 1996 Intestinal absorption of PLAGA microspheres in the rat. *J Anat* 189:491-501

20. Brubaker PL. Release of GLP-1 into the circulation. In: Fehmann H-C, Göke B, eds. *The insulintropic gut hormone glucagon-like peptide-1*. Basel: S.Karger AG, 1997:65-84.

21. Drucker DJ 1998 Glucagon-like peptides. *Diabetes* 47:159-169

22. Nauck MA, Heimesaat MM, Orskov C, Holst JJ, Ebert R, Creutzfeldt W 1993 Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. *J Clin Invest* 91:301-307

23. Hirota M, Hashimoto M, Hiratsuka M, Ohboshi C, Yoshimoto S, Yano M, Mizuno A, Shima K 1990 Alterations of plasma immunoreactive glucagon-like peptide-1 behavior in non-insulin-dependent diabetics. *Diabetes Res Clin Pract* 9:179-185

24. Gutniak M, Orskov C, Holst JJ, Ahrén B, Efendic S 1992 Antidiabetogenic effect of glucagon-like peptide-1 (7-36)amide in normal subjects and patients with diabetes mellitus. *N Engl J Med* 326:1316-1322

- 32 -

25. Deacon CF, Knudsen LB, Madsen K, Wiberg FC, Jacobsen O, Holst JJ 1998 Dipeptidyl peptidase IV resistant analogues of glucagon-like peptide-1 which have extended metabolic stability and improved biological activity. *Diabetologia* 41:271-278
- 5 26. Nauck MA, Holst JJ, Willms B, Schmiegel W 1997 Glucagon-like peptide 1 (GLP-1) as a new therapeutic approach for Type 2-diabetes. *Exp Clin Endocrinol Diabetes* 105:187-195
27. Kieffer TJ, McIntosh CHS, Pederson RA 1995 Degradation of glucose-dependent insulintropic polypeptide and truncated glucagon-like peptide 1 *in vitro* and *in vivo* by dipeptidyl peptidase IV. *Endocrinology* 10 136:3585-3596
28. Deacon CF, Johnsen AH, Holst JJ 1995 Degradation of glucagon-like peptide-1 by human plasma *in vitro* yields an N-terminally truncated peptide that is a major endogenous metabolite *in vivo*. *J Clin* 15 *Endocrinol Metab* 80:952-957
29. Gedulin BR, Young AA 1998 Hypoglycemia overrides amylin-mediated regulation of gastric emptying in rats. *Diabetes* 47:93-97
30. Brubaker PL, Lee YC, Drucker DJ 1992 Alterations in proglucagon processing and inhibition of proglucagon gene expression in transgenic mice which contain a chimeric proglucagon-SV40 T antigen gene. *J Biol Chem* 267:20728-20733 20
31. Brubaker PL, So DCY, Drucker DJ 1989 Tissue-specific differences in the levels of proglucagon-derived peptides in streptozotocin-induced diabetes. *Endocrinology* 124:3003-3009

- 33 -

32. Frisbie CD, Rozsnyai F, Noy A, Wrighton MS, Lieber CM. Functional group imaging by chemical force microscopy. Science 1994;265:2071-2074.(Abstract)
33. Chickering III DE, Jacob JS, Mathiowitz E 1995 Bioadhesive
5 microspheres, II. Characterization and evaluation of bioadhesion
involving hard, bioerodible polymers and soft tissue. Reactive Polymers
25:189-206
34. Chickering DE, Mathiowitz E 1995 Bioadhesive microspheres: I.
A novel electrobalance-based method to study adhesive interactions
10 between individual microspheres and intestinal mucosa. Journal of
Controlled Release 34:251-261
35. Park TG 1995 Degradation of poly(lactic-co-glycolic acid)
microspheres: effects of copolymer composition. Biomaterials 16:1123-1130
36. Kourti T. Particle size determination using dynamic light
15 scattering. 1989;A-062:(Abstract)
37. Kourti T, MacGregor JF, Hamielec AC, Nicoli DF, Elings V.
Polymer characterization by interdisciplinary methods. Washington, D.C.
ACS, 1989:
38. O'Hagan DT 1996 The intestinal uptake of particles and the
20 implications for drug and antigen delivery. J Anat 189:477-482
39. Schirra J, Leicht P, Hildebrand P, Beglinger C, Arnold R, Göke
B, Katschinski M 1998 Mechanisms of the antidiabetic action of
subcutaneous glucagon-like peptide-1(7-36)amide in non-insulin
dependent diabetes mellitus. J Endocr 156:177-186

- 34 -

40. Schirra J, Kuwert P, Wank U, Leicht P, Arnold R, Göke B, Katschinski M 1997 Differential effects of subcutaneous GLP-1 on gastric emptying, antroduodenal motility, and pancreatic function in men. *Proc Assoc Am Physicians* 109:84-97
- 5 41. Imeryüz N, Yegen B, Ç., Bozkurt A, Coskun T, Villanueva-Peñacarrillo ML, Ulusoy NB 1997 Glucagon-like peptide-1 inhibits gastric emptying via vagal afferent-mediated central mechanisms. *Am J Physiol Gastrointest Liver Physiol* 273:G920-G927
42. Desai MP, Labhasetwar V, Amidon GL, Levy RJ 1996
10 Gastrointestinal uptake of biodegradable microparticles: effects of particle size. *Pharm Res* 13:1838-1845
43. Florence AT 1997 The oral absorption of micro- and nanoparticulates: neither exceptional nor unusual. *Pharm Res* 14:259-266
44. Tabata Y, Inoue Y, Ikada Y 1996 Size effect on systemic and
15 mucosal immune responses induced by oral administration of biodegradable microspheres. *Vaccine* 14:1677-1685
45. Levine DS, Raisys VA, Ainardi V 1987 Coating of oral beclomethasone dipropionate capsules with cellulose acetate phthalate enhances delivery of topically active antiinflammatory drug to the
20 terminal ileum. *Gastroenterology* 92:1037-1044
46. Mentlein R, Gallwitz B, Schmidt WE 1993 Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum. *Eur J Biochem* 214:829-835

- 35 -

47. Pitt CG, Gu Z 1987 Modification of the rates of chain cleavage of poly(ϵ -caprolactone) and related polyesters in the solid state. *Journal of Controlled Release* 4:283-292
48. Pitt CG, Cha Y, Shah SS, Zhu KJ 1992 Blends of PVA and PGLA: control of the permeability and degradability of hydrogels by blending. *Journal of Controlled Release* 19:189-200
49. Göpferich A 1996 Mechanisms of polymer degradation and erosion. *Biomaterials* 17:103-114
50. Heller J 1980 Controlled release of biologically active compounds from bioerodible polymers. *Biomaterials* 1:51-57
51. Thomas NW, Jenkins PG, Howard KA, Smith MW, Lavelle EC, Holland J, Davis SS 1996 Particle uptake and translocation across epithelial membranes. *J Anat* 189:487-490
52. Eldridge JH, Hammond CJ, Meulbroek JA, Staas JK, Gilley RM, Tice TR 1990 Controlled release in the gut associated lymphoid tissue. I. orally administered biodegradable microspheres target the peyer's patches. *Journal of Controlled Release* 11:205-214
53. Jenkins PG, Howard KA, Blackhall NW, Thomas NW, Davis SS, O'Hagan DT 1994 Microparticulate absorption from the rat intestine. *Journal of Controlled Release* 29:339-350
54. Hillery AM, Jani PU, Florence AT 1994 Comparative, quantitative study of lymphoid and non-lymphoid uptake of 60 nm polystyrene particles. *Journal of Drug Targeting* 2:151-156

- 36 -

55. LeFevre ME, Hancock DC, Joel DD 1980 Intestinal barrier to large particulates in mice. *Journal of Toxicology and Environmental Health* 6:691-704
56. Kraehenbuhl JP, Neutra MR 1992 Molecular and cellular basis
5 of immune protection of mucosal surfaces. *Physiol Rev* 72:853-874
57. Owen RL, Nemanic P 1978 Antigen processing structures of the mammalian intestinal tract: an SEM study of lymphoepithelial organs. *Scanning Electron Microsc* 2:367-78
58. Owen RL, Ermark TH 1992 Structural specializations for
10 antigen uptake and processing in the digestive tract. *Springer Semin Immunopathol* 12:139-152
59. O'Leary AD, Sweeney EC 1986 Lymphoglandular complexes of the colon: structure and distribution. *Histopathol* 10:267-283
60. Langerman JM, Rowland R 1986 The number and distribution
15 of lymphoid follicles in the human large intestine. *J Anat* 194:189-194
61. Neutra MR, Pringault E, Kraehenbuhl JP 1996 Antigen sampling across epithelial barriers and induction of mucosal immune responses. *Annu Rev Immunol* 14:275-300
62. Chen H, Charlat O, Tartaglia LA, Woolf EA, Weng X, et al. 1996
20 Evidence that the diabetes gene encodes the leptin receptor: Identification of a mutation in the leptin receptor gene in db/db mice. *Cell* 84:491-495
63. Coleman DL 1978 Obese and diabetes: two Mutant genes causing diabetes-obesity syndrome in mice. *Diabetologia* 14:141-148

- 37 -

64. Chua SC, Chung WK, Wu-Peng XS, Zhang Y, Lui SM, et al.
1996 Phenotypes of mouse diabetes and rat fatty due to mutation in the Ob
(leptin) receptor. Science 271:994-996



FIG. 1A**FIG. 1B**



FIG. 2A**FIG. 2B**


FIGURE 3




FIG. 4A**FIG. 4B****FIG. 4C**

FIGURE 5





FIGURE 6


FIGURE 7


FIGURE 8




FIG. 9A**FIG. 9B****FIG. 9C**



FIG. 10A**FIG. 10B**


FIGURE 11

1

2

3

4



A

B

C

D

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

☐ **BLACK BORDERS**

☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**

☒ **FADED TEXT OR DRAWING**

☒ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**

☐ **SKEWED/SLANTED IMAGES**

☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**

☐ **GRAY SCALE DOCUMENTS**

☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**

☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**

☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.